In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme, with a price target of $79.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brendan Smith has given his Buy rating due to a combination of factors that highlight Halozyme’s strong financial performance and growth potential. The company reported impressive results for Q2, surpassing expectations in both revenue and earnings per share. This was largely driven by robust royalties from key products like Darzalex, Phesgo, and Vyvgart Hytrulo, which continue to perform well in the market.
Additionally, despite some uncertainties regarding CMS and IRA pricing timelines, Smith believes that Halozyme’s core business remains resilient. The company’s management has expressed confidence in their ongoing strategies, including potential new partnerships and product developments such as the ENHANZE technology. These factors collectively suggest a positive outlook for Halozyme, justifying the Buy rating.